HONG KONG, China I August 4, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II ...

TAIPEI, Taiwan I August 4, 2025 I Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New ...

STUTTGART, Germany I August 04, 2025 I La Merie Publishing released its newest product entitled: DLL3-Targeted Immunotherapy: a Competitor Analysis.

NEW YORK, NY, USA I August 01, 2025 I Spine BioPharma, Inc. announced today the Phase 3 MODEL trial (MOderate – Severe Degenerative Disc Disease Evaluation of the Lumbar Spine) evaluating SB-01, a TGF ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over ...

SHANGHAI, China I August 1, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its ...

STUTTGART, Germany I August 02, 2025 I La Merie Publishing released its newest product entitled: B7-H3-Targeted Immunotherapy: a Competitor Analysis.

Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of ...

EAST HANOVER, NJ, USA I July 31, 2025 I Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® ...

TAIPEI, Taiwan I August 1, 2025 I Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular energy restoration ...

EMERYVILLE, CA, USA I July 31, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...

Proteins and Peptides Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 ...